Literature DB >> 15182893

Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

Evgeny M Krupitsky1, Edwin E Zvartau, Dimitry V Masalov, Marina V Tsoi, Andrey M Burakov, Valentina Y Egorova, Tatyana Y Didenko, Tatyana N Romanova, Eva B Ivanova, Anton Y Bespalov, Elena V Verbitskaya, Nikolai G Neznanov, Alexandr Y Grinenko, Charles P O'Brien, George E Woody.   

Abstract

Naltrexone may be more effective for treating opioid (heroin) dependence in Russia than in the U.S. because patients are mostly young and living with their parents, who can control medication compliance. In this pilot study we randomized 52 consenting patients who completed detoxification in St. Petersburg to a double blind, 6-month course of biweekly drug counseling and naltrexone, or counseling and placebo naltrexone. Significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study. At the end of 6 months, 12 of the 27 naltrexone patients (44.4%) remained in treatment and had not relapsed as compared to 4 of 25 placebo patients (16%; p<0.05). Since heroin dependence is the main way HIV is being spread in Russia, naltrexone is likely to improve treatment outcome and help reduce the spread of HIV if it can be made more widely available.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15182893     DOI: 10.1016/j.jsat.2004.02.002

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  31 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

Review 2.  Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available.

Authors:  Evgeny Krupitsky; Edwin Zvartau; George Woody
Journal:  Curr Psychiatry Rep       Date:  2010-10       Impact factor: 5.285

3.  Anhedonia, depression, anxiety, and craving in opiate dependent patients stabilized on oral naltrexone or an extended release naltrexone implant.

Authors:  Evgeny Krupitsky; Edwin Zvartau; Elena Blokhina; Elena Verbitskaya; Valentina Wahlgren; Marina Tsoy-Podosenin; Natalia Bushara; Andrey Burakov; Dmitry Masalov; Tatyana Romanova; Arina Tyurina; Vladimir Palatkin; Tatyana Yaroslavtseva; Anna Pecoraro; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2016-07-19       Impact factor: 3.829

Review 4.  Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure.

Authors:  David H Epstein; Kenzie L Preston; Jane Stewart; Yavin Shaham
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

Review 5.  Oral naltrexone maintenance treatment for opioid dependence.

Authors:  Silvia Minozzi; Laura Amato; Simona Vecchi; Marina Davoli; Ursula Kirchmayer; Annette Verster
Journal:  Cochrane Database Syst Rev       Date:  2011-04-13

6.  The feasibility of HIV vaccine efficacy trials among Russian injection drug users.

Authors:  Chris Beyrer; Stefan Baral; Alla Shaboltas; Elena Dukhovlinova; Alexey Masharsky; Sergey Verevochkin; Carl Latkin; Robert Heimer; Irving Hoffman; Andrei Kozlov
Journal:  Vaccine       Date:  2007-08-03       Impact factor: 3.641

Review 7.  The pharmacological treatment of opioid addiction--a clinical perspective.

Authors:  Philipp Lobmaier; Michael Gossop; Helge Waal; Jorgen Bramness
Journal:  Eur J Clin Pharmacol       Date:  2010-02-19       Impact factor: 2.953

8.  Addiction Science: A Rationale and Tools for a Public Health Response to Drug Abuse.

Authors:  Richard A Rawson; Traci Rieckmann; Steven W Gust
Journal:  Public Health Rev       Date:  2014

Review 9.  Naltrexone: A Pan-Addiction Treatment?

Authors:  Elias Aboujaoude; Wael O Salame
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

Review 10.  Antagonist Models for Relapse Prevention and Reducing HIV Risk.

Authors:  George E Woody; Evgeny Krupitsky; Edwin Zvartau
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-27       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.